{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Blaney SM"],"funding":["5 U01","NCRR","NCRR NIH HHS","NCI NIH HHS"],"pagination":["627-32"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC3573253"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["60(4)"],"pubmed_abstract":["<h4>Purpose</h4>We performed a phase-1 pharmacokinetic optimal dosing study of intraventricular topotecan (IT), administered daily 5×, to determine whether, the maximum tolerated dose of IT topotecan was also the pharmacokinetic optimal dose.<h4>Patients and methods</h4>Patients received topotecan administered through an intraventricular access device (0.1 or 0.2 mg/dose), daily × 5 every other week 2× (Induction); every 3 weeks × 2 (Consolidation); then every 4 weeks for up to 11 courses (Maintenance). Ventricular CSF pharmacokinetic studies were performed on day 1, week 1 of induction, and in a subset of patients after a single intralumbar topotecan dose on day 1, week 3.<h4>Results</h4>Nineteen patients were enrolled. All were evaluable for toxicity and 18 were assessable for pharmacoki"],"journal":["Pediatric blood & cancer"],"pubmed_title":["A phase-1 pharmacokinetic optimal dosing study of intraventricular topotecan for children with neoplastic meningitis: a Pediatric Brain Tumor Consortium study."],"pmcid":["PMC3573253"],"funding_grant_id":["U01 CA081457","CA81457","M01 RR00188","M01 RR000188"],"pubmed_authors":["Boyett J","Blaney SM","Kun L","Onar-Thomas A","Stewart C","Berg SL","Su J","Tagen M","Scorsone K","Goldman S","Kieran MW","Gururangan S"],"additional_accession":[]},"is_claimable":false,"name":"A phase-1 pharmacokinetic optimal dosing study of intraventricular topotecan for children with neoplastic meningitis: a Pediatric Brain Tumor Consortium study.","description":"<h4>Purpose</h4>We performed a phase-1 pharmacokinetic optimal dosing study of intraventricular topotecan (IT), administered daily 5×, to determine whether, the maximum tolerated dose of IT topotecan was also the pharmacokinetic optimal dose.<h4>Patients and methods</h4>Patients received topotecan administered through an intraventricular access device (0.1 or 0.2 mg/dose), daily × 5 every other week 2× (Induction); every 3 weeks × 2 (Consolidation); then every 4 weeks for up to 11 courses (Maintenance). Ventricular CSF pharmacokinetic studies were performed on day 1, week 1 of induction, and in a subset of patients after a single intralumbar topotecan dose on day 1, week 3.<h4>Results</h4>Nineteen patients were enrolled. All were evaluable for toxicity and 18 were assessable for pharmacoki","dates":{"release":"2013-01-01T00:00:00Z","publication":"2013 Apr","modification":"2025-04-26T08:55:24.193Z","creation":"2019-03-27T01:04:52Z"},"accession":"S-EPMC3573253","cross_references":{"pubmed":["23002039"],"doi":["10.1002/pbc.24309"]}}